{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T18:34:56Z","timestamp":1786991696889,"version":"build-2736575974"},"reference-count":12,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100007915","name":"Baylor College of Medicine","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007915","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["canadianjournalofophthalmology.ca","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Canadian Journal of Ophthalmology"],"published-print":{"date-parts":[[2022,2]]},"DOI":"10.1016\/j.jcjo.2021.04.018","type":"journal-article","created":{"date-parts":[[2021,5,28]],"date-time":"2021-05-28T03:17:23Z","timestamp":1622171843000},"page":"e6-e10","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":32,"title":["Papilledema and hypervitaminosis A after elexacaftor\/tezacaftor\/ivacaftor for cystic fibrosis"],"prefix":"10.1016","volume":"57","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4910-3436","authenticated-orcid":false,"given":"Matthew J.","family":"Miller","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7937-830X","authenticated-orcid":false,"given":"Rod","family":"Foroozan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jcjo.2021.04.018_bib0001","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1002\/j.1536-4801.1990.tb09983.x","article-title":"Vitamin A in cystic fibrosis: case report and review of the literature","volume":"10","author":"Eid","year":"1990","journal-title":"J Pediatr Gastroenterol Nutr"},{"key":"10.1016\/j.jcjo.2021.04.018_bib0002","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1016\/j.jcf.2019.03.009","article-title":"An open-label extension study of ivacaftor in children with CF and a CFTR gating mutation initiating treatment at age 2\u20135\u202fyears (KLIMB)","volume":"18","author":"Rosenfeld","year":"2019","journal-title":"J. Cyst Fibros."},{"key":"10.1016\/j.jcjo.2021.04.018_bib0003","doi-asserted-by":"crossref","first-page":"2001","DOI":"10.1007\/s40265-019-01233-7","article-title":"Elexacaftor\/ivacaftor\/tezacaftor: first approval","volume":"79","author":"Hoy","year":"2019","journal-title":"Drugs"},{"key":"10.1016\/j.jcjo.2021.04.018_bib0004","unstructured":"Safety and Possible Side Effects | TRIKAFTA (elexacaftor\/tezacaftor\/ivacaftor and ivacaftor). www.trikafta.com\/safety-side-effects [accessed September 21, 2020]."},{"key":"10.1016\/j.jcjo.2021.04.018_bib0005","doi-asserted-by":"crossref","first-page":"e81","DOI":"10.1038\/ctg.2017.10","article-title":"Impact of CFTR modulation on intestinal pH, motility, and clinical outcomes in patients with cystic fibrosis and the G551D mutation","volume":"8","author":"Gelfond","year":"2017","journal-title":"Clin Transl Gastroenterol"},{"key":"10.1016\/j.jcjo.2021.04.018_bib0006","doi-asserted-by":"crossref","DOI":"10.1016\/j.jpeds.2018.05.018","article-title":"Energy balance and mechanisms of weight gain with ivacaftor treatment of cystic fibrosis gating mutations","volume":"201","author":"Stallings","year":"2018","journal-title":"J Pediatr"},{"key":"10.1016\/j.jcjo.2021.04.018_bib0007","doi-asserted-by":"crossref","first-page":"483","DOI":"10.3390\/antiox10030483","article-title":"CFTR modulator therapy with lumacaftor\/ivacaftor alters plasma concentrations of lipid-soluble vitamins A and E in patients with cystic fibrosis","volume":"10","author":"Sommerburg","year":"2021","journal-title":"Antioxidants"},{"key":"10.1016\/j.jcjo.2021.04.018_bib0008","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/j.jns.2016.11.014","article-title":"Role of vitamin A metabolism in IIH: results from the idiopathic intracranial hypertension treatment trial","volume":"372","author":"Libien","year":"2017","journal-title":"J Neurol Sci"},{"key":"10.1016\/j.jcjo.2021.04.018_bib0009","first-page":"81","article-title":"Laboratory medicine best practice guideline: vitamins A, E and the carotenoids in blood","volume":"35","author":"Greaves","year":"2014","journal-title":"Clin Biochem Rev"},{"key":"10.1016\/j.jcjo.2021.04.018_bib0010","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1210\/er.2012-1071","article-title":"Vitamin A metabolism, action, and role in skeletal homeostasis","volume":"34","author":"Conaway","year":"2013","journal-title":"Endocr Rev"},{"key":"10.1016\/j.jcjo.2021.04.018_bib0011","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1542\/peds.2006-0167","article-title":"Risk of vitamin A toxicity from candy-like chewable vitamin supplements for children","volume":"118","author":"Lam","year":"2006","journal-title":"Pediatrics"},{"key":"10.1016\/j.jcjo.2021.04.018_bib0012","doi-asserted-by":"crossref","first-page":"1244","DOI":"10.1513\/AnnalsATS.201404-170BC","article-title":"Hypervitaminosis A causing hypercalcemia in cystic fibrosis. case report and focused review","volume":"11","author":"Safi","year":"2014","journal-title":"Ann Am Thorac Soc"}],"container-title":["Canadian Journal of Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0008418221001629?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0008418221001629?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,13]],"date-time":"2025-09-13T20:10:27Z","timestamp":1757794227000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0008418221001629"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,2]]},"references-count":12,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,2]]}},"alternative-id":["S0008418221001629"],"URL":"https:\/\/doi.org\/10.1016\/j.jcjo.2021.04.018","relation":{},"ISSN":["0008-4182"],"issn-type":[{"value":"0008-4182","type":"print"}],"subject":[],"published":{"date-parts":[[2022,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Papilledema and hypervitaminosis A after elexacaftor\/tezacaftor\/ivacaftor for cystic fibrosis","name":"articletitle","label":"Article Title"},{"value":"Canadian Journal of Ophthalmology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jcjo.2021.04.018","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Canadian Ophthalmological Society. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}